Annual CFF
$15.23 M
-$512.80 K-3.26%
December 31, 2023
Summary
- As of February 7, 2025, ENTO annual cash flow from financing activities is $15.23 million, with the most recent change of -$512.80 thousand (-3.26%) on December 31, 2023.
- During the last 3 years, ENTO annual CFF has fallen by -$1.82 million (-10.67%).
- ENTO annual CFF is now -65.98% below its all-time high of $44.76 million, reached on December 1, 2021.
Performance
ENTO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.55 M
+$871.40 K+127.88%
September 1, 2024
Summary
- As of February 7, 2025, ENTO quarterly cash flow from financing activities is $1.55 million, with the most recent change of +$871.40 thousand (+127.88%) on September 1, 2024.
- Over the past year, ENTO quarterly CFF has dropped by -$2.81 million (-64.38%).
- ENTO quarterly CFF is now -90.90% below its all-time high of $17.07 million, reached on December 1, 2021.
Performance
ENTO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$9.97 M
-$3.83 M-27.77%
September 1, 2024
Summary
- As of February 7, 2025, ENTO TTM cash flow from financing activities is $9.97 million, with the most recent change of -$3.83 million (-27.77%) on September 1, 2024.
- Over the past year, ENTO TTM CFF has dropped by -$5.25 million (-34.51%).
- ENTO TTM CFF is now -77.72% below its all-time high of $44.76 million, reached on December 1, 2021.
Performance
ENTO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ENTO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.3% | -64.4% | -34.5% |
| 3 y3 years | -10.7% | -56.2% | -28.4% |
| 5 y5 years | +30.0% | -64.7% | -28.4% |
ENTO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -66.0% | at low | -90.9% | +1932.5% | -77.7% | at low |
| 5 y | 5-year | -66.0% | +15.8% | -90.9% | +1932.5% | -77.7% | +3.0% |
| alltime | all time | -66.0% | +225.3% | -90.9% | +595.8% | -77.7% | +759.6% |
Entero Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.55 M(+127.9%) | $9.97 M(-27.8%) |
| Jun 2024 | - | $681.40 K(-79.8%) | $13.81 M(-8.3%) |
| Mar 2024 | - | $3.38 M(-22.5%) | $15.06 M(-1.1%) |
| Dec 2023 | $15.23 M(-3.3%) | $4.36 M(-19.1%) | $15.23 M(-7.1%) |
| Sep 2023 | - | $5.39 M(+178.7%) | $16.39 M(+3.9%) |
| Jun 2023 | - | $1.93 M(-45.5%) | $15.78 M(+13.3%) |
| Mar 2023 | - | $3.55 M(-35.8%) | $13.92 M(-11.6%) |
| Dec 2022 | $15.74 M(-64.8%) | - | - |
| Dec 2022 | - | $5.52 M(+15.8%) | $15.74 M(-42.3%) |
| Sep 2022 | - | $4.77 M(+6145.8%) | $27.29 M(-27.0%) |
| Jun 2022 | - | $76.40 K(-98.6%) | $37.37 M(-4.4%) |
| Mar 2022 | - | $5.37 M(-68.6%) | $39.08 M(-12.7%) |
| Dec 2021 | $44.76 M(+162.6%) | $17.07 M(+14.9%) | $44.76 M(+58.5%) |
| Sep 2021 | - | $14.86 M(+733.8%) | $28.24 M(+6.8%) |
| Jun 2021 | - | $1.78 M(-83.9%) | $26.45 M(+4.4%) |
| Mar 2021 | - | $11.05 M(+1900.5%) | $25.34 M(+48.7%) |
| Dec 2020 | $17.05 M(+29.7%) | $552.40 K(-95.8%) | $17.05 M(-7.1%) |
| Sep 2020 | - | $13.06 M(+1828.3%) | $18.34 M(+89.4%) |
| Jun 2020 | - | $677.30 K(-75.4%) | $9.68 M(-30.5%) |
| Mar 2020 | - | $2.76 M(+49.3%) | $13.93 M(+6.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $13.14 M(+12.2%) | $1.85 M(-58.1%) | $13.14 M(+13.8%) |
| Sep 2019 | - | $4.40 M(-10.6%) | $11.55 M(+69.0%) |
| Jun 2019 | - | $4.93 M(+150.5%) | $6.84 M(-40.2%) |
| Mar 2019 | - | $1.97 M(+671.4%) | $11.43 M(-2.4%) |
| Dec 2018 | $11.71 M(+94.8%) | $255.00 K(-181.4%) | $11.71 M(+0.8%) |
| Sep 2018 | - | -$313.20 K(-103.3%) | $11.62 M(-5.3%) |
| Jun 2018 | - | $9.52 M(+324.1%) | $12.27 M(+47.2%) |
| Mar 2018 | - | $2.25 M(+1310.6%) | $8.34 M(+38.6%) |
| Dec 2017 | $6.01 M(+4.6%) | $159.20 K(-52.9%) | $6.01 M(-36.7%) |
| Sep 2017 | - | $338.00 K(-94.0%) | $9.51 M(+3.7%) |
| Jun 2017 | - | $5.59 M(-7336.0%) | $9.17 M(+68.4%) |
| Mar 2017 | - | -$77.30 K(-102.1%) | $5.44 M(-5.3%) |
| Dec 2016 | $5.75 M(+22.8%) | $3.65 M(>+9900.0%) | $5.75 M(+221.8%) |
| Sep 2016 | - | $0.00(-100.0%) | $1.79 M(-64.1%) |
| Jun 2016 | - | $1.87 M(+730.7%) | $4.97 M(+32.7%) |
| Mar 2016 | - | $225.00 K(-173.0%) | $3.75 M(-20.0%) |
| Dec 2015 | $4.68 M | -$308.20 K(-109.7%) | $4.68 M(-6.2%) |
| Sep 2015 | - | $3.19 M(+394.6%) | $4.99 M(+176.6%) |
| Jun 2015 | - | $644.00 K(-44.5%) | $1.80 M(+55.5%) |
| Mar 2015 | - | $1.16 M | $1.16 M |
FAQ
- What is Entero Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Entero Therapeutics?
- What is Entero Therapeutics annual CFF year-on-year change?
- What is Entero Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Entero Therapeutics?
- What is Entero Therapeutics quarterly CFF year-on-year change?
- What is Entero Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Entero Therapeutics?
- What is Entero Therapeutics TTM CFF year-on-year change?
What is Entero Therapeutics annual cash flow from financing activities?
The current annual CFF of ENTO is $15.23 M
What is the all time high annual CFF for Entero Therapeutics?
Entero Therapeutics all-time high annual cash flow from financing activities is $44.76 M
What is Entero Therapeutics annual CFF year-on-year change?
Over the past year, ENTO annual cash flow from financing activities has changed by -$512.80 K (-3.26%)
What is Entero Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ENTO is $1.55 M
What is the all time high quarterly CFF for Entero Therapeutics?
Entero Therapeutics all-time high quarterly cash flow from financing activities is $17.07 M
What is Entero Therapeutics quarterly CFF year-on-year change?
Over the past year, ENTO quarterly cash flow from financing activities has changed by -$2.81 M (-64.38%)
What is Entero Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ENTO is $9.97 M
What is the all time high TTM CFF for Entero Therapeutics?
Entero Therapeutics all-time high TTM cash flow from financing activities is $44.76 M
What is Entero Therapeutics TTM CFF year-on-year change?
Over the past year, ENTO TTM cash flow from financing activities has changed by -$5.25 M (-34.51%)